52 results about "Celecoxib" patented technology

The invention belongs to the technical field of biomedical anti-inflammatory gels, and discloses a renewable boundary lubrication natural polyphenol anti-inflammatory hydrogel and a preparation method and application thereof.The hydrogel is of a hydrophilic viscoelastic sea island structure, gallic acid grafted gelatin blended with hyaluronic acid serves as a base material, celecoxib lipidosome is entrapped in the hydrogel, and the hydrogel is prepared from natural polyphenols, an articular cavity is injected through an enzyme crosslinking technology to form gel, hyaluronic acid and lipidosome form a hydrated lubricating layer on a cartilage-gel interface, and after the interface is abraded, internal lipidosome and hyaluronic acid are exposed to supplement lubrication so as to form sustainable lubrication; the liposome responds to friction shear crushing to release celecoxib and cooperates with gallic acid at an interface to resist inflammation progress and repair cartilage, the injectable hydrogel is developed based on gallic acid, hyaluronic acid, gelatin and celecoxib liposome to treat early osteoarthritis, mechanical lubrication and inflammation resistance are combined, and the preparation method has the advantages that the preparation method is simple, the preparation cost is low, and the application prospect is wide. The problems of large-dose toxicity, short lubrication period and the like caused by independent treatment are effectively solved, and the preparation has important clinical application significance.

The application relates to a celecoxib capsule composition and belongs to the technical field of pharmaceutical preparations. The celecoxib capsule composition is prepared from the following components in percentage by weight: celecoxib 74.1%, lactose monohydrate 16.4%-17.4%, arginine 1.0%-2.0%, sodium dodecyl sulfate 3.0%, povidone (K30) 2.5%, cross-linked sodium carboxymethyl cellulose 1.0%, and magnesium stearate 1.0%. The problem that the dissolution curve of the celecoxib capsule is significantly slowed down during storage is solved by adding appropriate arginine in the prescription.

The application belongs to the technical field of wound dressings, and discloses a water-based gel dressing with antibacterial and scar prevention effects and a preparation method, wherein 3-fluoro-4-carboxyphenylboronic acid is introduced to graft chitooligosaccharide, a large number of catechol structures in tannic acid solution are combined with the phenylboronic acid bond to form a dynamic boron ester bond, and a network gel structure is formed by responding to the supermolecular forces such as hydrogen bonds, wherein the boron ester bond can be broken in response to the high ROS level of the wound microenvironment and the acidic environment caused by bacterial infection, so as to efficiently release celecoxib, a selective non-steroidal anti-inflammatory drug of cyclooxygenase-2, and the liposome of verteporfin is limited in volume and stays in the dressing for a longer time, so that the sustained and stable release can be maintained in the whole wound healing process, thereby achieving the effects of on-demand inflammation regulation and long-acting mechanical response regulation.

The invention provides a substrate-free anti-inflammatory hydrogel microneedle particle and a preparation method thereof. The microneedle particle comprises an anti-inflammatory active component and a microneedle substrate used for wrapping the anti-inflammatory active component, the anti-inflammatory active component is selected from any one of curcumin, celecoxib and aesculin; the hydrogel is prepared from hyaluronic acid. A substrate of a traditional microneedle is abandoned, and the problems of displacement and falling caused by sweat or skin deformation are avoided. The raw materials of the microneedle particles are safe, no chemical cross-linking agent is used during preparation, and the risks of inducing local allergy and aggravating oxidative stress are avoided. The substrate-free microneedle particles have higher flexibility and contact area, and can be better attached to the skin, so that the delivery efficiency of drugs can be improved.

The invention provides a lipidosome preparation capable of performing brain-targeted drug delivery in a depression model, a preparation method of the lipidosome preparation and application of the lipidosome preparation in improving the anti-depression effect of fluoxetine, and belongs to the technical field of pharmaceutical preparations. The composition disclosed by the invention consists of DOPG, DSPE-PEG2000-PGP, DSPE-PEG2000, cholesterol, fluoxetine and celecoxib, and can be used for improving the anti-depression effect of fluoxetine. The double-drug-loading liposome with high entrapment efficiency and uniform particle size is prepared through a film hydration-film extrusion method, has good stability and biocompatibility, has an obvious targeting drug delivery effect in a chronic social contusion stress model, is suitable for a combined treatment strategy of depression, and has a good clinical application prospect.

The present invention provides a celecoxib cream and a preparation method thereof, and belongs to the technical field of pharmaceutical preparations, the celecoxib cream comprises, by mass, 0.5%-2% of celecoxib, 1%-20% of an oily matrix, 1%-20% of an emulsifier, 0.1%-10% of a transdermal absorption enhancer, 1%-20% of a thickener, 2%-15% of a humectant, 0.1%-2% of a preservative, 0.1%-10% of a pH regulator, and the balance of deionized water. The prepared celecoxib cream is good in stability and high in bioavailability, and gastrointestinal reaction and oral first pass effect of a traditional oral dosage form are avoided. The celecoxib cream disclosed by the invention is also added with a transdermal absorption enhancer, so that medicine molecules can be helped to penetrate through a skin barrier and directly reach a focus part; the metabolism loss of the medicine on the skin surface can be reduced, more active ingredients enter blood circulation or deep tissues, the local treatment effect is enhanced, and the important clinical value is achieved.

The invention belongs to the technical field of wound dressings, and discloses a hydrogel dressing with antibacterial and scar-preventing effects and a preparation method thereof.3-fluoro-4-carboxyphenylboronic acid grafted chitosan oligosaccharide is introduced, phenylboronic acid bonds are matched with a large number of catechol structures in a tannic acid solution to form dynamic boron ester bonds, and the dynamic boron ester bonds are grafted to the chitosan oligosaccharide; the preparation method comprises the following steps: carrying out joint response with supramolecular forces such as hydrogen bonds to form a network gel structure, enabling boron ester bonds to respond to a high ROS level of a wound microenvironment and an acidic environment caused by bacterial infection to break, so as to efficiently release cyclooxygenase-2 selective non-steroidal anti-inflammatory drug celecoxib, and enabling the vinipofen liposome to be limited by a relatively large volume, so that the vinipofen liposome has a good anti-inflammatory effect. The time of staying in the dressing is longer, and continuous and stable release can be maintained in the whole wound healing process range, so that the effects of on-demand inflammation regulation and control and long-acting mechanical response regulation and control are achieved.

An embodiment relates to a tablet comprising celecoxib, and ciprofloxacin or a pharma- ceutically acceptable salt thereof, and a low viscosity hydroxypropyl methylcellulose having a viscosity of less than 150 cP when measured as a 2% solution in water at 20°C.

The invention provides application of a CD5-targeting reagent in the aspects of reducing the drug resistance of tumor cells and improving the anti-tumor curative effect of drugs, and clarifies for the first time that CD5 molecules can promote high expression and cell nucleus displacement of transcription factors FOXO3a and FOXO4 in a forkhead cassette O signal channel; therefore, expression increase of the ABC drug-resistant protein family in diffuse large B-cell lymphoma tumor cells is mediated, and drug resistance of tumor cells to various chemotherapeutic drugs is promoted. Further, it is found that the celecoxib can significantly inhibit expression of CD5 molecule mediated ABC drug-resistant protein in B-cell lymphoma cells, then the celecoxib and chemotherapeutic drugs are combined for application, the killing effect of traditional chemotherapeutic drugs on diffuse large B-cell lymphoma tumor cells is significantly enhanced, and the chemotherapeutic drug resistance of diffuse large B-cell lymphoma is overcome. The anti-drug-resistant tumor strategy can overcome the problems of low treatment response rate and poor prognosis of the CD5-positive diffuse large B-cell lymphoma to the existing chemotherapy regimen due to multidrug resistance, and significantly improves the anti-tumor treatment effect.

The present invention relates to a pharmaceutical composition which comprises the synergistic combination of a selective inhibitor of cyclooxygenase-2, such as the active ingredient: celecoxib and its pharmaceutically acceptable salts, and a carbamate derived from guaifenesin, such as the active ingredient: methocarbamol and its pharmaceutically acceptable salts, which are formulated with pharmaceutically acceptable excipients and / or carriers and / or additives in a single dosage unit to be orally, dermally or transdermally or topically administered, which is also indicated in the treatment of pain, inflammation and muscular contractions, wherein said combination has a triple analgesic, anti-inflammatory and muscle-relaxing effect, and is better tolerated and has less side effects in patients with pain, inflammation and muscular contraction.

The present disclosure relates to methods of treating Alzheimer's disease, diseases and / or conditions associated with Covid-19 infection, including long COVID, a post-acute infection syndrome, or symptoms of orthostatic intolerance comprising administration of a therapeutically-effective combination of a COX-2 inhibitor and an antiviral compound.

The invention discloses a pharmaceutical composition containing gramine and application thereof.The pharmaceutical composition comprises gramine and celecoxib, and the mass ratio of gramine to celecoxib is 1: 1. The pharmaceutical composition with the effect of relieving ulcerative colitis (UC) has the advantages that the effect of relieving the ulcerative colitis (UC) is achieved, and the pharmaceutical composition can be used for treating the ulcerative colitis; a preclinical experiment result shows that the pharmaceutical composition provided by the invention has a good effect of treating ulcerative colitis. In the in-vivo and in-vitro UC morbidity process, 3% DSS induces a mouse UC model and LPS stimulates NCM460 cells to trigger an inflammatory reaction along with the increase of the inflammatory factor level; the pharmaceutical composition can inhibit the expression of inflammatory factors PTGS2, TNF-alpha, IL-1beta and IL-6, can protect the intestinal barrier, and significantly increases the expression of Occludin, Claudin-1 and ZO-1 proteins. The pharmaceutical composition is convenient and simple in administration route, has no obvious adverse reaction, can be developed into a new generation of medicine for relieving the ulcerative colitis, and is expected to become a good prescription for treating the ulcerative colitis.

The invention discloses an application of celecoxib or a pharmaceutical salt thereof in preparation of an antifungal drug synergist. An antifungal drug is selected from an azole antifungal drug, an allylamine antifungal drug or an echinocandin antifungal drug. The azole antifungal drug is selected from the group consisting of fluconazole, voriconazole, itraconazole, posaconazole and isavuconazole; the allylamine antifungal drug is selected from terbinafine; the echinocandin antifungal drug is selected from caspofungin. In-vivo and in-vitro experiments prove that when the celecoxib is combined with the azole antifungal drug and the allylamine antifungal drug terbinafine, a synergistic antifungal effect is shown, and when the celecoxib is combined with the echinocandin antifungal drug caspofungin, an additive effect is shown. Celecoxib and fluconazole are combined for use, so that the survival rate of fungal infected animals can be increased, and toxicity to wax moth larvae and mammalian cells is low.

The present application relates to a celecoxib-vitamin E prodrug. The celecoxib-vitamin E prodrug is prepared by connecting celecoxib with vitamin E by means of a dithio-bis-acetic acid. The catalysts used include: dicyclohexyl carbodiimide (DCC), 4-dimethylaminopyridine (DMAP). The prodrug has some characteristics: uniform distribution in a spherical shape, the average particle size is about 700 nm, the drug loading can reach 4 mg•mL ‑1 The prodrug can improve the bioavailability of celecoxib, and the preparation method thereof is disclosed.

The utility model discloses specific gravity detection alarm equipment for celecoxib production, which comprises a detection cylinder, an installation disc is fixed on the detection cylinder, an alarm box is arranged on the installation disc, a controller and an audible and visual alarm are arranged on the alarm box, a floating ring and a floating cylinder are arranged in the detection cylinder, the floating ring is sleeved outside the floating cylinder, and the controller is connected with the audible and visual alarm. A distance measuring sensor is installed on the floating ring and used for detecting the distance between the floating ring and the floating cylinder, the floating ring and the floating cylinder are supported through a bracket, the edge of the bracket extends out of a strip groove in the surface of the detection cylinder and is provided with a sliding sleeve, a screw penetrates through the sliding sleeve and is in threaded connection with the sliding sleeve, and one end of the screw is connected with a motor. The floating ring and the floating cylinder can directly extend into the reaction kettle for easy specific gravity detection, the trouble of repeated sampling detection is saved, and the floating ring and the floating cylinder can lift and move under the control of the sliding sleeve and the screw rod, so that the floating ring and the floating cylinder can be lifted to be away from a solution during stirring reaction in the reaction kettle, and the solution is prevented from overturning the floating ring and the floating cylinder.

The present invention discloses a ROS-enhanced liposome and its preparation method and application, which relates to the technical field of biomedical polymer materials and new dosage forms of pharmaceutical preparations. The liposome is composed of egg yolk lecithin, cholesterol and DSPE-mPEG. 2K The liposome is a membrane material prepared by a thin film dispersion extrusion method to encapsulate different drugs; wherein the drug is a ROS-responsive celecoxib dimer prodrug (CTC); or a combination of a ROS-responsive celecoxib dimer prodrug (CTC) and sinomenine hydrochloride (SIN); or a combination of a ROS-responsive celecoxib dimer prodrug (CTC), sinomenine hydrochloride (SIN) and L-butionine-(S,R)-sulfoximine (L-BSO). The liposome not only has the advantages of good stability and long circulation time, but also can target and enrich RA tissues through ELVIS, release celecoxib in a high ROS environment, and then combine with sinomenine hydrochloride to achieve a combined therapeutic effect.

This disclosure relates to methods for treating diseases and / or conditions (including long COVID) associated with Covid-19 infection, the methods comprising administering a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nematvir and ritonavir, monorapvir, a BCG vaccine, or ivermectin.

The invention belongs to the technical field of pharmaceutical preparations, and discloses a celecoxib tablet and a preparation method thereof.The celecoxib tablet is composed of celecoxib, lactose-microcrystalline cellulose compounded according to a specific proportion, polyvinylpolypyrrolidone-carboxymethyl starch sodium, a lubricant and a solubilizing stabilizer. Wherein the solubilizing stabilizer is beta-cyclodextrin, sodium stearoyl lactylate and meglumine. The preparation method comprises the steps of pretreatment of the celecoxib and the solubilizing stabilizer, step-by-step granulation, drying and size stabilization, and total mixing and tabletting. Through the synergistic effect of the compound solubilizing stabilizer and the wet grinding process and in combination with the preparation method of step-by-step mixing granulation, the content uniformity, the dissolution performance and the storage stability of the prepared celecoxib tablet are remarkably improved, and the preparation process is simple and easy to operate and suitable for industrial large-scale production.

The scheme discloses a triple-negative breast cancer targeting drug and preparation and application, proposes a combination drug of paclitaxel and celecoxib, and uses a polypeptide modified liposome to deliver the combination drug, realizes target co-delivery of the combination drug, and improves the effectiveness of ICD and the rejection of the anti-tumor immune response in triple-negative breast cancer through the joint action of paclitaxel and celecoxib in a reasonable proportion, and the experiment proves that the combination drug has good therapeutic effect and recurrence and metastasis inhibition effect.

The invention relates to the technical field of biology, in particular to novel application of sanguinarine (SAN), a method for inducing human amniotic mesenchymal stem cells (hAMSCs) to be differentiated into osteoblasts through COX2 protein and an osteogenic induction culture medium for the inducing method, and the method can be applied to the fields of bone disease treatment drug research and development and clinical transformation. It is proved for the first time that SAN mediates hAMSCs osteogenic differentiation through COX2 protein, SAN can significantly improve expression of COX2 gene (PTGS2) in hAMSCs, the osteogenic effect of SAN can be reversed by adding a COX2 inhibitor (such as celecoxib), and direct experimental evidence is provided for'COX2 serving as a small molecule drug to promote osteogenic differentiation '.

The invention relates to the field of pharmacy, and discloses a celecoxib nanoemulsion, a gel emplastrum and a preparation method of the celecoxib nanoemulsion and the gel emplastrum. The celecoxib nano-emulsion is an oil-in-water nano-emulsion with the emulsion particle size of less than 50nm, and comprises the following raw materials: 0.2-5% of celecoxib, 1-35% of an oil-phase substance, 1-30% of an emulsifier, 1-25% of a co-emulsifier, 0.1-10% of a penetration enhancer and 30-75% of water, the preparation method comprises the following steps: firstly, preparing the celecoxib into an oil-in-water type nano-emulsion, then adding the oil-in-water type nano-emulsion into a hydrophilic gel matrix to prepare a paste body, and finally preparing the gel plaster. On one hand, the prepared celecoxib nanoemulsion has excellent stability; and on the other hand, the prepared celecoxib nanoemulsion has extremely small particle size (less than 50nm), is transparent, is beneficial to diffusion and permeation of celecoxib in skin, and is easier to absorb. The celecoxib nano-emulsion gel plaster is an external plaster dosage form, and compared with a conventional oral preparation, the celecoxib nano-emulsion gel plaster has the advantages of no first-pass effect, few side effects, high bioavailability and more comfortable and convenient use.

The present disclosure relates to use of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the present disclosure is used for treating inflammatory depression, wherein the pharmaceutical composition comprises: (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition of the present disclosure is directed to inflammatory depression (especially inflammatory treatment-resistant depression and anhedonia depression).

The application relates to the technical field of medicines, and particularly discloses a class of celecoxib derivatives, a preparation method and application thereof. The derivative is formed by connecting celecoxib and straight-chain amino acids through a chemical bond, and the straight-chain amino acids are glycine, gamma-aminobutyric acid and the like. The derivative or a pharmaceutically acceptable salt and a pharmaceutical composition thereof can be used for preparing medicines for preventing and / or treating pain or nervous system diseases. The derivative has excellent water solubility, strong COX-2 inhibitory activity, good analgesic activity and anti-inflammatory activity, has good analgesic effects on inflammatory pain, neuropathic pain and visceral pain and the like, and has a wide application prospect.

The present disclosure relates to uses of a pharmaceutical composition. Specifically, the pharmaceutical composition provided by the invention is used for treating inflammatory depression, and the pharmaceutical composition comprises (i) dextromethorphan or a salt of dextromethorphan and (ii) celecoxib or a salt of celecoxib. The pharmaceutical composition disclosed by the invention is used for treating inflammatory depression (especially inflammatory refractory depression and pleasant sensation deficiency type depression).

The invention provides an osteoarthritis analgesic enteric capsule containing a non-steroidal anti-inflammatory component, and relates to the technical field of pharmaceutical preparations. The osteoarthritis analgesic enteric capsule containing the non-steroidal anti-inflammatory component comprises an enteric capsule shell and a content, and is characterized in that the content comprises iguratimod and celecoxib which serve as active components, and the content is composed of two independent enteric coated pellets: A type pellets, B type pellets, C type pellets and D type pellets, comprising a celecoxib-containing drug-loaded pellet core and an enteric coating layer coating the celecoxib-containing drug-loaded pellet core, the B-type pellet comprises a drug-loaded pellet core containing iguratimod and an enteric coating layer coating the drug-loaded pellet core; the A-type pellets and the B-type pellets are physically mixed according to a certain proportion and then are filled in the same enteric capsule shell. Celecoxib and iguratimod are adopted, Celecoxib provides rapid and powerful pain relief, iguratimod inhibits inflammation pathways from multiple targets and provides cartilage protection, and the combination of Celecoxib and iguratimod realizes the synergistic effect of treating both symptoms and root causes.

This invention discloses a ternary nanoparticle, its preparation method, and its applications, relating to the field of biomedical technology. The invention constructs a carrier-free, fully active ternary nanoparticle (diPCL NPs). This nanoplatform connects PTX dimer (diPTX), celecoxib (CXB) dimer (diCXB), and lonidamine (LND) dimer (diLND) via disulfide bonds for chemoimmunotherapy of drug-resistant tumors. diPCL NPs accumulate at tumor sites through enhanced permeability and retention (EPR) effects and circulate continuously in the bloodstream. In the high GSH tumor microenvironment, disulfide bond cleavage releases the active drug, exerting chemotherapeutic, immune-activating, sensitizing, and metabolic-regulating effects. diPCL NPs exhibit high antitumor efficacy and good safety profile within the therapeutic window in both breast cancer and paclitaxel-resistant models.

The application belongs to the technical field of medical devices, and specifically discloses an anti-tumor electrospun scaffold and a preparation method thereof. The anti-tumor electrospun scaffold comprises a drug-loaded electrospun scaffold body and tumor cell-derived drug-loaded micro-particles loaded on the surface of the scaffold body. The drug-loaded electrospun scaffold body comprises amino polymers, hydrophilic polymers and celecoxib with a mass ratio of (2-10):(2-13):1, which are prepared by using an electrospinning technology, and has a high specific surface area and a high porosity. The loading amount of the tumor cell-derived doxorubicin-loaded micro-particles on the anti-tumor electrospun scaffold is 0.6 μg / mg-6.1 μg / mg. The drug is directly delivered to a tumor resection cavity in the form of in-situ implantation, long-term drug retention, continuous drug release and complete degradation of the scaffold material are achieved. Residual tumor cells are effectively killed, the tumor immune microenvironment is reshaped, and the recurrence and metastasis of the tumor are inhibited.